European endocrinologists have experience in prescribing biosimilar human growth hormone and insulin glargine; however, the uptake of these biosimilars varies by each country under study. New biosimilar products reaching the market such as Eli Lilly’s Basaglar (insulin glargine follow-on biologic) due to launch in the United States in December 2016 could have a significant impact on prescription dynamics among diabetes patients. Such dynamics will be driven by physician perceptions, and their understanding of and concerns about biosimilar products. This content is based on surveys with endocrinologists in the United States, France, and Germany, aiming to gain an understanding of their attitudes, perspectives on biosimilars, as well as current and future trends in biosimilar use.